AMR Drug Pipeline: Beta-Lactamase & Phage Therapy — PatSnap Eureka
Novel Beta-Lactamase Inhibitors, Phage Therapy & Gram-Negative AMR Approaches
Carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa are WHO critical-priority pathogens. Explore the full pipeline — from FDA-approved BL/BLI combinations to artilysins, AI-designed peptides, and nematode-derived antibiotics — powered by PatSnap Eureka's patent and literature intelligence.
WHO Critical-Priority Pathogens Driving the AMR Crisis
Antimicrobial resistance (AMR) represents one of the most urgent threats to global public health. The most frequently cited organisms across the AMR drug pipeline dataset are Klebsiella pneumoniae (KPC, OXA, and MBL carbapenemase producers), Acinetobacter baumannii (carbapenem-resistant; CRAB), and Pseudomonas aeruginosa (carbapenem-resistant; CRPA) — all ranked as WHO critical-priority organisms for new treatment development.
The molecular determinants of resistance span four primary categories. Serine beta-lactamases — KPC (class A), OXA-type (class D), AmpC (class C), and ESBL enzymes — are the primary targets for novel beta-lactamase inhibitor (BLI) development. Ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam were specifically developed to inhibit KPC and ESBL-class enzymes.
Metallo-beta-lactamases (MBLs) — class B enzymes including NDM, VIM, and IMP — hydrolyze virtually all beta-lactams. As of the dataset's coverage, no clinically available MBL inhibitor exists, representing the most critical unmet need in the BL/BLI space. PatSnap's life sciences intelligence platform tracks this gap in real time across global patent filings.
Outer membrane permeability barriers — including porin channel loss (OmpK35/36 in K. pneumoniae) and upregulation of RND-family efflux pumps (MexAB-OprM in P. aeruginosa) — further limit drug penetration. The LPS outer membrane is specifically flagged as the primary obstacle to Gram-negative activity for endolysins and some antimicrobial peptide (AMP) classes. The CDC classifies carbapenem-resistant Enterobacteriaceae as urgent threats.
Clinically Advanced BL/BLI Agents: Approved & Late-Stage Pipeline
The most clinically advanced modality cluster in the AMR dataset, with multiple FDA-approved agents and next-generation combinations in late-stage evaluation targeting MBL-producing strains.
| Agent / Combination | BLI Class / Mechanism | Primary Target Enzymes | Key Pathogen Coverage | Stage |
|---|---|---|---|---|
| Ceftazidime/avibactam (Avycaz) | Diazabicyclooctane (DBO) non-beta-lactam BLI | KPC, ESBL, OXA-48, AmpC | CRE, CRPA | FDA Approved 2015 |
| Meropenem/vaborbactam | Cyclic boronic acid BLI | KPC producers | KPC-producing CRE | FDA Approved |
| Imipenem/relebactam | Piperidine-linked DBO-class BLI | KPC, ESBL | KPC-producing CRE, P. aeruginosa | FDA Approved 2019 |
| Ceftolozane/tazobactam | Tazobactam BLI | AmpC (overexpressing) | AmpC-overexpressing CRPA | FDA Approved |
| Cefiderocol | Siderophore-conjugated cephalosporin | Iron-uptake channel penetration (not BLI) | CRAB, P. aeruginosa pneumonia | FDA Approved 2019 |
| Aztreonam/avibactam | DBO BLI + monobactam | MBL-producing strains (NDM coverage signal) | MBL-producing CRE | Late-Stage |
| Cefepime/taniborbactam | Boronic acid BLI (next-gen) | KPC, MBL (partial) | MDR Enterobacteriaceae, CRPA | Clinical Eval. |
| Cefepime/zidebactam | DBO BLI with PBP2 binding | Broad-spectrum serine BLI + PBP2 | MDR Gram-negatives | Clinical Eval. |
Track Resistance Emergence Across Approved BL/BLI Combinations
Resistance to novel BL/BLI combinations is already documented — driven by porin deficiencies and enzyme mutations. PatSnap Eureka monitors the evolving resistance landscape in real time.
AMR Therapeutic Modalities: Development Stage & Research Activity
Patent and literature analysis via PatSnap Eureka reveals distinct maturity profiles across AMR therapeutic modalities — from FDA-approved BL/BLI combinations to preclinical phage therapy and AI-designed peptides.
AMR Modalities by Clinical Maturity
BL/BLI combinations are the most clinically advanced cluster. AMPs represent the largest preclinical research volume. Phage therapy is transitioning from compassionate use to combination paradigm.
BL/BLI Coverage Gap: MBL vs. Serine Beta-Lactamases
Approved BL/BLI combinations cover serine beta-lactamases (KPC, OXA-48, ESBL, AmpC) but leave metallo-beta-lactamase (MBL/NDM/VIM)-producing strains without a clinically available inhibitor.
Phage Therapy, Artilysins & Antimicrobial Peptides for MDR Gram-Negatives
Beyond BL/BLI combinations, the AMR pipeline includes phage-derived enzybiotics, AI-designed peptides, and novel small molecules targeting previously unexploited mechanisms in WHO critical-priority pathogens.
Whole-Phage & Artilysin Approaches Against CRAB and CRPA
Phage therapy is identified as a "promising alternative therapy with renewed research in Western countries," specifically directed at WHO critical-priority pathogens for which antibiotics have failed. Retrieved results report in vitro, in vivo, and early clinical case evidence against carbapenem-resistant A. baumannii, P. aeruginosa, and ESBL-producing Enterobacteriaceae. Phage therapy demonstrates superior efficacy when combined with antibiotics, including in biofilm settings. KU Leuven developed artilysins — engineered endolysins fused with polycationic nonapeptide domains — that are highly bactericidal against P. aeruginosa and A. baumannii, overcoming the LPS outer membrane barrier. The NIH supports phage therapy research as part of the broader AMR response strategy.
Preclinical + Early Clinical CasesAI-Designed & Engineered AMPs: PLG0206, PrAMPs & Neural-Net Peptides
AMPs represent the largest modality cluster in the dataset by source count. An LSTM recurrent neural network approach from Stavropol State Medical University generated 198 novel peptide sequences, of which PEP-38 and PEP-137 showed in vitro activity against carbapenem-resistant K. pneumoniae and in vivo activity in a murine sepsis model. Engineered AMP PLG0206 demonstrated activity against more than 1,200 MDR ESKAPEE clinical isolates in animal models (UTI, prosthetic joint infection), with "continuing clinical development" cited as a supported trajectory. Proline-rich AMPs (PrAMPs) targeting intracellular DnaK showed synergy with meropenem against carbapenemase-expressing K. pneumoniae and A. baumannii. PatSnap's life sciences intelligence tracks AMP patent filings globally.
Predominantly PreclinicalDarobactin, Odilorhabdins & Nematode Microbiome-Derived Antibiotics
Darobactin — a ribosomally synthesized antibiotic from Photorhabdus symbionts — targets the BamA outer membrane protein complex, a mechanism absent in human cells with no prior approved drug. Northeastern University reports potent in vitro and in vivo activity against Gram-negative pathogens. Odilorhabdins (ODLs) from Xenorhabdus/Photorhabdus species inhibit bacterial translation by binding to the small ribosomal subunit at a site distinct from all classical antibiotics — the first new Gram-negative translation class introduced in more than 40 years. Both originate from entomopathogenic nematode symbionts, an ecological niche identified as underexplored relative to traditional soil microbiome sources. PatSnap Analytics enables landscape analysis of natural product antibiotic filings.
Early-to-Mid DevelopmentPhage + Antibiotic, AMP + Colistin & Adjuvant Approaches
Combination strategies are a dominant paradigm for treating pan-drug-resistant and difficult-to-treat (DTR) Gram-negative infections. Phage–antibiotic synergy is particularly potent in biofilm-associated infections. AMP combinations include NuriPep 1653 + colistin against pan-drug-resistant A. baumannii, PrAMP (A3-APO) + colistin or meropenem, and PMBN + azithromycin against MDR E. coli. University of Liège describes pyrazole compounds devoid of direct antibacterial activity that display synergistic activity with existing antibiotics against colistin- and carbapenem-resistant A. baumannii. Monash University describes polymyxin/non-antibiotic combinations as a strategy to preserve last-line agents. The EMA monitors combination antibiotic approvals for MDR pathogens.
Preclinical + Clinical EvidenceKey AMR Pipeline Signals & Strategic Implications
Retrieved patent and literature evidence surfaces five high-priority strategic signals for AMR drug developers, IP strategists, and investors — from the MBL inhibitor gap to the repositioning of phage therapy.
MBL Inhibitor Gap: The Most Critical Unmet Need in BL/BLI
No clinically available MBL inhibitor exists. Metallo-beta-lactamase-producing strains remain poorly covered by all current BL/BLI combinations including avibactam and vaborbactam. Aztreonam/avibactam is the most advanced signal for bridging this gap. IP strategies targeting novel MBL-binding scaffolds — zinc-chelating cyclic boronate or thiol-based inhibitors — represent a high-priority and potentially defensible claim space.
Resistance to Approved BL/BLI Combinations Is Emerging Rapidly
Real-world resistance to ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam is documented — driven by enzyme mutations and porin deficiencies — compressing the clinical utility window. Development programs for next-generation combinations (cefepime/taniborbactam, cefepime/zidebactam) should be evaluated with acquired resistance dynamics as a primary consideration.
Who Is Driving AMR Innovation? Academic Institutions Dominate
Activity in the AMR drug pipeline dataset is almost entirely literature-driven (academic papers), with no patents retrieved in this dataset. This may reflect search configuration rather than the true commercial IP landscape, and should be interpreted accordingly. Academic and governmental institutions dominate across all five therapeutic modalities.
Key institutions by modality: Northeastern University (Boston) leads darobactin discovery via community ecology-inspired antibiotic screening. KU Leuven (Belgium) pioneered artilysin engineering for Gram-negative endolysins. Nosopharm (Nîmes, France) represents an industry-academic crossover for odilorhabdin drug discovery from nematode-symbiotic bacteria. Walter Reed Army Institute of Research (USA) leads PrAMP ARV-1502 preclinical development. University of Pittsburgh (USA) developed engineered AMP PLG0206 with broad-spectrum ESKAPEE activity and in vivo validation.
Clinical institutions in Italy, Greece, Spain, and the USA contribute predominantly to clinical pipeline reviews and real-world BL/BLI combination evidence — including University of Pisa, Erasmus MC Rotterdam, Attikon University Hospital Athens, and Hartford Hospital. PatSnap customers in pharma and biotech use Eureka to benchmark against this institutional landscape. The EPO tracks AMR-related patent filings as part of its technology-in-focus reporting.
The absence of commercial patent data in this dataset signals a gap between academic publication and patent filing in phage therapy and AMP modalities specifically. PatSnap Analytics enables a dedicated IP landscape search to surface commercial assignee activity not captured in literature-only searches. PatSnap's open API allows programmatic access to this data for large-scale landscape analysis.
FDA-Approved AMR Agents: Approval Timeline 2015–2019
The dataset documents a concentrated wave of FDA approvals for novel BL/BLI combinations and related agents between 2015 and 2019, representing confirmed regulatory milestones.
FDA-Approved AMR Agents: Regulatory Milestones 2015–2019
Seven AMR agents received FDA approval between 2015 and 2019 — including ceftazidime/avibactam (2015), plazomicin and eravacycline (2018), and imipenem/relebactam and cefiderocol (2019). Resistance emergence to several of these agents is already documented in clinical settings.
Antimicrobial Resistance Drug Pipeline — key questions answered
The most clinically advanced cluster is beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. FDA-approved agents include ceftazidime/avibactam (2015), ceftolozane/tazobactam, meropenem/vaborbactam, imipenem/relebactam (2019), plazomicin (2018), eravacycline (2018), and cefiderocol (2019). Next-generation combinations including aztreonam/avibactam and cefepime/taniborbactam are in late-stage clinical evaluation.
Metallo-beta-lactamases (MBLs) — including NDM, VIM, and IMP — hydrolyze virtually all beta-lactams and are resistant to current BLI scaffolds including avibactam and vaborbactam. As of the dataset's coverage, no clinically available MBL inhibitor exists. Aztreonam/avibactam is the most advanced signal for bridging this gap, though porin-loss-driven resistance even to this combination has been documented.
Phage therapy uses bacteriophages — viruses that infect bacteria — to target carbapenem-resistant organisms including A. baumannii, P. aeruginosa, and ESBL-producing Enterobacteriaceae. Retrieved results report that phage therapy demonstrates superior efficacy when combined with antibiotics, including in biofilm settings. Engineered artilysins (endolysins fused with polycationic peptide domains) have been developed at KU Leuven to overcome the LPS outer membrane barrier in Gram-negative pathogens.
Darobactin is a ribosomally synthesized antibiotic from Photorhabdus symbionts with a bicyclic ring structure. It targets the BamA outer membrane protein complex — a mechanism absent in human cells and with no prior approved drug. Northeastern University reports potent activity against Gram-negative pathogens both in vitro and in vivo. Darobactin originates from screening of entomopathogenic nematode symbionts, an ecological niche identified as underexplored relative to traditional soil microbiome sources.
Retrieved results uniformly note proteolytic stability, systemic toxicity, and pharmacokinetic liabilities as limiting clinical translation of AMPs. Rationally engineered candidates such as PLG0206, dioctanoyl ultrashort tetrabasic beta-peptides (dUSTBβPs), and AI-designed PEPs represent the translational vanguard. Developers should prioritize candidates with demonstrated in vivo efficacy data and characterized ADME/toxicity profiles over those with in vitro MIC data alone.
A University of Queensland pipeline review (October 2019) enumerated 44 small-molecule antibacterials, 8 BLI combinations, and 1 antibody-drug conjugate (ADC) in worldwide clinical trials at that snapshot date.
Still have questions about the AMR pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About AMRAccelerate Your AMR Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to navigate the beta-lactamase inhibitor landscape, track phage therapy patents, and identify unmet needs in Gram-negative AMR.
References
- Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology — Hartford Hospital, 2020
- New antibiotics for Gram-negative pneumonia — University of Genova, 2022
- Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics — University of Trieste, 2022
- Drug development concerning metallo-β-lactamases in gram-negative bacteria — Shandong Provincial Maternal and Child Health Care Hospital, 2022
- The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa — University of Liverpool, 2021
- Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives — Hospital La Fe Valencia, 2022
- Engineered Endolysin-Based "Artilysins" To Combat Multidrug-Resistant Gram-Negative Pathogens — KU Leuven, 2014
- The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How — National and Kapodistrian University of Athens, 2019
- New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections — Hospital Clinic of Barcelona, 2022
- Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens — IIS-Fundación Jiménez Díaz, Madrid, 2021
- Endolysin, a Promising Solution against Antimicrobial Resistance — Northwest University, Xi'an, 2021
- Novel Antimicrobial Peptides Designed Using a Recurrent Neural Network Reduce Mortality in Experimental Sepsis — Stavropol State Medical University, 2022
- Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class — University of Pittsburgh, 2022
- Synergy Between Proline-Rich Antimicrobial Peptides and Small Molecule Antibiotics Against Selected Gram-Negative Pathogens in vitro and in vivo — Walter Reed Army Institute of Research, 2018
- A new antibiotic selectively kills Gram-negative pathogens — Northeastern University, 2019
- From Worms to Drug Candidate: The Story of Odilorhabdins, a New Class of Antimicrobial Agents — Nosopharm, 2019
- New Broad-Spectrum Antibiotics Containing a Pyrrolobenzodiazepine Ring with Activity against Multidrug-Resistant Gram-Negative Bacteria — Public Health England, 2020
- Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli — IRCCS Bologna, 2022
- Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use — University of Milano-Bicocca, 2021
- World Health Organization (WHO) — Priority Pathogens List for AMR Research and Development
- CDC — Antibiotic Resistance Threats in the United States
- NIH — National Institute of Allergy and Infectious Diseases: Antimicrobial Resistance Program
- European Patent Office (EPO) — Technology in Focus: Antimicrobial Resistance
- European Medicines Agency (EMA) — Antimicrobial Resistance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.